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Abstract 
 
Title: Anesthetic Considerations for the Parturient with Immune Thrombocytopenic Purpura 
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune disease that accounts 
for 5% of pregnancy-associated thrombocytopenia. The condition in the parturient is associated 
with complications that include maternal hemorrhage and fetal intracranial hemorrhage. 
Furthermore, it places the parturient at increased risk of developing neurologic complications 
following administration of neuraxial anesthesia. Although the incidence of ITP is low, 
anesthetists should be informed of the condition to prevent potentially fatal complications.  
Purpose: The purpose of this independent project is to present a case report and provide 
anesthesia providers with evidence-based research regarding the anesthetic considerations for 
parturients with ITP.  
Process: A review of the literature was performed using PubMed and CINAHL databases from 
the University of North Dakota’s Harley E. French Library of the Health Sciences. Each 
reference utilized was carefully scrutinized for inclusion within the review.  
Results: ITP is an autoimmune disorder that accelerates the rate of platelet destruction and leads 
to persistent thrombocytopenia. Frequent monitoring of maternal and fetal wellbeing as well as 
collaboration among the obstetrician, hematologist, anesthetist, and neonatologist is required to 
mitigate complications. Antepartum management may include administration of oral 
corticosteroids or intravenous immunoglobulins (IVIg) depending on clinical manifestations and 
maternal platelet counts. Additionally, life-threatening bleeding or emergent delivery may 
necessitate platelet transfusion in conjunction with IVIg infusion. The mode of delivery is 
dependent on the maternal condition and obstetrical indicators with the primary goal of 
maintaining a platelet count greater than 50,000 per microliter (mcL) to minimize the risk of 
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maternal hemorrhage during both vaginal and cesarean delivery. Controversy exists regarding 
the lowest safe platelet count required for administration of neuraxial anesthesia in the parturient 
with thrombocytopenia. Several studies have proposed utilizing thromboelastography (TEG) and 
rotational thromboelastometry (ROTEM) to help guide safe anesthetic practices. Due to 
inadequate evidence and conflicting reports, the use of TEG/ROTEM as well as a minimally safe 
platelet count cannot be supported at this time. Current evidence suggests that the provision of 
neuraxial anesthesia in thrombocytopenic parturients be considered on an individual basis after 
conducting a careful risk-benefit analysis.  
Implications: By understanding the pathophysiology, potential complications, and anesthetic 
considerations associated with ITP in the parturient, maternal and neonatal morbidity and 
mortality may be reduced. 
Keywords: Immune thrombocytopenia, thrombocytopenia, pregnancy, obstetrical anesthesia, 
spinal anesthesia, and cesarean section.  
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Anesthetic Considerations for the Parturient with Immune Thrombocytopenic Purpura 
Thrombocytopenia is a clinical condition in which there is a decreased number of 
circulating platelets (Berkley & Kilpatrick, 2009). It complicates approximately 7% of all 
pregnancies and may result from a number of causes (Berkley & Kilpatrick, 2009). No matter the 
etiology, all forms of thrombocytopenia can be attributed to either increased platelet destruction 
or decreased platelet production (Berkley & Kilpatrick, 2009). Immune thrombocytopenic 
purpura (ITP) is an autoimmune disease that accounts for 5% of pregnancy-associated 
thrombocytopenia (Stavroe & McCrae, 2009). Hallmark features of the condition include platelet 
destruction resulting in platelet counts less than 100,000 per microliter (mcL) with no clinically 
apparent cause (Berkley & Kilpatrick, 2009). The major complications associated with ITP are 
maternal hemorrhage and fetal thrombocytopenia with potential fetal intracranial hemorrhage 
(Hindley, 2016).   
Providing anesthesia to a parturient is challenging due to the anatomic and physiologic 
changes that occur during healthy pregnancies (Nagelhout & Plaus, 2014). When pregnancy is 
complicated by ITP, anesthesia providers are presented with a unique situation that requires 
careful consideration and planning. Currently, neuraxial anesthesia is considered the favorable 
method of anesthesia for labor and delivery (Nagelhout & Plaus, 2014). It has significant 
advantages over general anesthesia as a primary anesthetic including decreased risk of maternal 
mortality and more favorable neonatal outcomes (Nagelhout & Plaus, 2014). Unfortunately, the 
presence of thrombocytopenia places the parturient at risk for developing spinal-epidural 
hematomas that may result in permanent neurologic injury (Bernstein et al., 2016). Controversy 
exists regarding the lowest safe platelet count required for administration of neuraxial anesthesia. 
PARTURIENT WITH IMMUNE THROMBOCYTOPENIC PURPURA 
	
6 
Ultimately, it is the anesthesia providers responsibility to weigh the risks and benefits of 
anesthesia modalities in this unique population (Myers, 2012; Provan et al., 2010).  
 Obviously, the combination of pregnancy and ITP would be considered a low occurrence, 
high stakes situation that requires thorough anesthetic planning and vigilant monitoring. In the 
following pages, a case report of a parturient with chronic ITP who underwent a planned 
cesarean section is presented. A literature review that covers the pathophysiology, diagnosis, 
clinical presentation and anesthetic considerations for ITP will follow.  
Purpose 
 The purpose of this independent project is to present a case report and provide anesthesia 
providers with evidence-based research regarding the anesthetic management of a parturient with 
ITP. By understanding the pathophysiology, potential complications, and anesthetic 
considerations associated with this condition, maternal and neonatal morbidity and mortality may 
be reduced.  
Case Report 
 A 23-year-old, 90 kg, 155 cm, Native American female presented for a planned repeat 
cesarean section for intrauterine pregnancy at 36-weeks gestation with incomplete uterine 
rupture. She denied having any allergies. Her medical history included chronic ITP, anxiety, 
depression, and iron deficiency anemia. Obstetric history included gravida four and para three. 
She received late prenatal care in her third trimester of pregnancy, and her ITP was not medically 
managed. Surgical history included three previous cesarean sections and laparoscopic 
cholecystectomy. There was no history of anesthetic complications. Current medications 
included cyanocobalamin, vitamin B6, prenatal multivitamin, and iron supplement. Pertinent labs 
included hemoglobin 12.4 g/dL, hematocrit 37.2%, and a stable platelet count of 87,000 per 
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mcL. Additionally, she was type and screened for two units of packed red blood cells (PRBCs), 
which were retrieved from lab prior to the start of the case.  
 The patient was considered an American Society of Anesthesiologists (ASA) physical 
status level two with a Mallampati class II airway. Bilateral breath sounds were clear to 
auscultation. Normal S1 and S2 heart sounds with regular rate and rhythm were noted upon 
cardiovascular exam. Preoperative vital signs were: heart rate 72/min, blood pressure 122/70 
mmHg, respirations 12/min, oxygen saturation (SpO2) 99% on room air, and temperature 36.1° 
Celsius. Fetal heart monitoring showed 140-150 beats per minute, moderate variability, reactive 
accelerations, and absent decelerations.  
 Prior to transport to the operating room, an intravenous (IV) lactated ringers bolus of 
1000 mL was administered via a 20-gauge IV catheter by obstetric nursing staff. A new bag of 
lactated ringers was initiated, and the infusion was maintained continuously. The patient was 
transferred to the operating room where she was assisted into a sitting position on the operating 
table. Non-invasive monitors were applied which included: a finger pulse oximeter, a five-lead 
electrocardiogram (EKG), and a blood pressure cuff.  
 The patient was instructed to arch her back into a flexed position with assistance from 
nursing staff. Vital signs were: heart rate 91/min with normal sinus rhythm, blood pressure 
134/76 mmHg, and SpO2 99% on room air. The patient’s back was cleansed, utilizing sterile 
technique, with betadine solution, and a sterile drape was applied. Three milliliters (mL) of 1% 
lidocaine without epinephrine was administered for local infiltration in a fan-like pattern at the 
L3-L4 inter-spinous space. A blunt bevel 20-gauge introducer needle was advanced into the 
Ligamentum Flavum via a midline approach. A 25-gauge, 3.5-inch pencil point spinal needle 
was then inserted through the introducer. After a positive loss of resistance, the stylet was 
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withdrawn, and clear, free-flowing cerebrospinal fluid (CSF) return was confirmed. A syringe 
containing 1.6 mL 0.75% bupivacaine/8.25% dextrose, 20 mcg fentanyl, and 0.2 mg Duramorph 
was attached to the spinal needle. The syringe was gently aspirated for positive CSF return 
followed by slow injection of the entire volume into the intrathecal space. The spinal needle and 
introducer were removed simultaneously without incident.  
 The patient was repositioned in the supine position with left uterine displacement. 
Bilateral arms were secured on arm boards and abducted less than 90 degrees. Oxygen was 
applied via nasal cannula at 3 L/minute with end-tidal carbon dioxide (ETCO2) monitoring 
present. A skin probe was placed in the left axillary fold for temperature monitoring. Vital signs 
were reassessed and found to be: heart rate 114/min, blood pressure 86/62 mmHg, SpO2 100%, 
and temperature 36.2° Celsius. A phenylephrine 100 mcg bolus was administered IV for 
hypotension. Three minutes later, vital signs were reassessed and found to be: heart rate 95/min, 
blood pressure 106/64 mmHg, SpO2 100%, and temperature 36.2° Celsius. Due to the patient’s 
increased risk of hemorrhage, an 18-gauge IV catheter was placed in addition to the pre-existing 
20-gauge IV catheter. An IV infusion of normal saline via blood tubing was connected to the 18-
gauge catheter and infused continuously. Two grams of cefazolin IV was administered for a 
preoperative antibiotic. The abdomen was prepped to the level of the xiphoid process, and Foley 
catheter placed by nursing staff. The patient denied sensation to the T6 dermatome distribution 
during application of antiseptic prep solution. Prior to incision, the surgeon utilized forceps to 
assess the height of the intrathecal blockade. Once again, the patient denied sensation below the 
T6 dermatome level.  
 The surgical incision was made ten minutes after intrathecal injection. Prior to uterine 
incision, the surgeon noted an intact uterus with a uterine window. The 2.55 kg neonate was 
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delivered nine minutes after surgical incision, and an IV infusion of 20 units oxytocin in a 1000 
mL bag of lactated ringers was initiated. Neonatal Apgar scores were assessed by neonatal 
intensive care unit (NICU) nursing staff and noted to be nine (60 seconds after delivery) and nine 
(5 minutes after delivery). Seven minutes after delivery of the neonate, the patient complained of 
nausea. Vital signs noted to be: heart rate 86/min, blood pressure 128/72 mmHg, SpO2 100%, 
and temperature 36.3° Celsius. Four mg of ondansetron was administered with relief of nausea. 
The abdominal wound was closed by the surgeon. The neonate was transferred to the NICU, and 
the patient was transferred to the post-anesthesia care unit (PACU). The patient was administered 
diphenhydramine 25 mg IV in PACU for itching, but had an otherwise uneventful recovery. 
 During the 1-hour 25-minute surgical procedure, the patient received a total of 1000 mL 
of normal saline, 1400 mL of lactated ringers, and 500 mL of lactated ringers with 20 units 
oxytocin. Estimated blood loss was 500 mL, and urine output was 400 mL. The patient and 
neonate had an uneventful hospital stay and were discharged home on postoperative day four.  
Literature Search  
 According to Stillwell, Fineout-Overholt, Melnyk, & Williamson (2010), a literature 
search using the Cochrane Library, PubMed, and CINAHL will result in the strongest level of 
evidence. For this literature search, PubMed and CINAHL databases were accessed via the 
Harley E. French Health Sciences Library. PubMed and CINAHL were utilized because they 
contain medical, scientific, nursing, and allied health literature that applies to the clinical inquiry 
presented (Stillwell et al., 2010).  
Keywords and Limits 
 A total of four searches were conducted using Medical Subject Heading (MeSH) terms 
within the PubMed database. Using MeSH terms results in a comprehensive literature search by 
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finding all articles related to the keywords. The first search utilized the MeSH terms “anesthesia, 
obstetrical” and “thrombocytopenia” in all fields. This resulted in 66 articles. To make the 
number of articles more manageable, the limits “within ten years,” “humans,” and “full text” 
were applied. This decreased the search results to 19, with four articles specifically pertinent to 
the topic of interest.  
 The second search using PubMed was performed using the MeSH terms “cesarean 
section” and “thrombocytopenia” in all fields. This search produced 273 results. The search was 
further refined by adding the search filters “within ten years,” “humans,” and “free full text.” 
This decreased the search results to 15 articles, with one article specifically pertinent to the topic 
of interest.   
 The third search performed with PubMed used the MeSH terms “thrombocytopenia” and 
“spinal anesthesia.” Nineteen articles resulted from this search. The limits “within ten years,” 
“humans,” and “full text” were applied. This exploration reduced the results to 10 with one 
pertinent article saved for the review.  
 CINAHL was the next database chosen for the literature search. A total of three searches 
were conducted using the CINAHL database. First, the search words “idiopathic 
thrombocytopenia” and “pregnancy” were used with the all text option. This yielded 14 results. 
The search was further refined by using the limits “published dates between 2008 and 2017”, 
“peer-reviewed,” “academic journals,” and “English language.” The application of these limits 
resulted in six articles, three of which were saved for review.  
 The second search within the CINAHL database utilized the search words 
“thrombocytopenia” and “cesarean section” with the all text option. This resulted in 27 articles. 
After applying the limits “published dates between 2007 and 2018”, “peer-reviewed,” “academic 
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journals,” and “English language,” the results were further reduced to 11 articles. One article was 
a duplicate, and two articles were saved.   
 The third search within the CINAHL database utilized the search words “spinal 
anesthesia” and “thrombocytopenia” with the all text option. This resulted in seven articles. After 
applying the limits “published dates between 2007 and 2018”, “peer-reviewed,” “academic 
journals,” and “English language,” the results were further reduced to three articles. One article 
was a duplicate, and two articles were saved.    
 Additionally, four applicable articles were found by reviewing the reference list of 
evidence-based research articles that had already been evaluated. The identification of key search 
terms as well as the use of controlled vocabulary within credible healthcare focused databases 
proved to be an effective and efficient literature search strategy. After searches within PubMed 
and CINAHL databases had been completed, a total of seventeen articles were saved and 
reviewed. A detailed review of the literature will be discussed in the following section. 
Review of Literature  
Pathophysiology and Diagnosis  
 The normal platelet count in women ranges from 150,000 to 400,000 per mcL (Berkley & 
Kilpatrick, 2009; Hindley, 2016). However, this value is often lower in parturients due to the 
expansion of plasma volume, hemodilution, and increased platelet activation and clearance that 
occurs with healthy pregnancies (Berkley & Kilpatrick, 2009; Provan et al., 2010). 
Thrombocytopenia is clinically defined as a platelet count less than 150,000 per mcL and is a 
relatively common syndrome that affects approximately 7% of all pregnancies (Stavroe & 
McCrae, 2009). Thrombocytopenia during pregnancy is associated with many etiologies 
including infections, folic acid deficiency, hematologic disorders, immunologic destruction, and 
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excess bleeding (Berkley & Kilpatrick, 2009). No matter the etiology, all forms of 
thrombocytopenia can be attributed to either increased platelet destruction or decreased platelet 
production (Berkley & Kilpatrick, 2009; Hindley, 2016; Stavroe & McCrae, 2009). 
 ITP is a thrombocytopenic syndrome that accounts for 5% of pregnancy-associated 
thrombocytopenia (Stavroe & McCrae, 2009). ITP is an autoimmune disorder that involves the 
formation of IgG antiplatelet antibodies that recognize specific antigens on platelet membranes 
(Stavroe & McCrae, 2009; Wyszynski et al., 2016). The binding of the IgG antibodies to the 
platelet membrane marks the platelet for destruction by the reticuloendothelial system in the 
spleen (Stavroe & McCrae, 2009; Wyszynski et al., 2016). This accelerates the rate of platelet 
destruction and leads to persistent thrombocytopenia (Stavroe & McCrae, 2009; Wyszynski et 
al., 2016). The clinical presentation of ITP can be variable and can occur in both pregnant and 
non-pregnant individuals (Stavroe & McCrae, 2009). It more commonly presents as an 
asymptomatic disorder that is detected with routine laboratory testing (Stavroe & McCrae, 2009). 
However, some patients may present with a history of gingival bleeding, epistaxis, easy bruising, 
and petechiae (Berkley & Kilpatrick, 2009).  
ITP is considered a diagnosis of exclusion because no specific platelet count threshold 
has been identified and platelet antibody tests do not help to differentiate between 
thrombocytopenic disorders (Stavroe & McCrae, 2009). A diagnosis of ITP is often made when a 
platelet count of less than 100,000 per mcL is present with an otherwise normal complete blood 
count and no clinically apparent causes of thrombocytopenia (Berkley & Kilpatrick, 2009; 
Stavroe & McCrae, 2009; Wyszynski et al., 2016). However, the diagnosis of ITP is more likely 
if the patient presents with a prior history of thrombocytopenia, severe thrombocytopenia 
(platelet count less than 50,000 per mcL), and/or underlying autoimmune disease (Stavroe & 
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McCrae, 2009). ITP can be diagnosed as an acute or chronic condition and is considered chronic 
when the thrombocytopenia persists for more than six months (Wyszynski et al., 2016). 
Interestingly, women with previously diagnosed ITP or chronic ITP can experience an 
exacerbation or relapse of the condition during pregnancy (Provan et al., 2010; Stavroe & 
McCrae, 2009).  
Complications  
Most pregnancies complicated by ITP are uneventful and result in good outcomes for 
both the mother and the neonate (Provan et al., 2010). However, frequent prenatal monitoring of 
maternal and fetal wellbeing is required to mitigate complications (Hindley, 2016; Myers 2012). 
The major complication associated with ITP in the parturient is excessive or spontaneous 
hemorrhage during the intrapartum and postpartum periods (Berkley & Kilpatrick, 2009; 
Hindley, 2016). The risk of hemorrhage is directly linked to the maternal platelet count, but 
rarely occurs with platelet counts greater than 20,000 per mcL (Berkley & Kilpatrick, 2009). 
According to Provan et al. (2010), current literature indicates that women with ITP have a low 
risk of maternal and fetal hemorrhage and can safely tolerate pregnancy. 
The major complication associated with ITP in the fetus is the development of fetal 
thrombocytopenia and subsequent fetal intracranial hemorrhage (Hindley 2016; Stavroe & 
McCrae, 2009). The maternal IgG antibodies are actively transported into fetal circulation 
through the placenta (Hindley 2016; Stavroe & McCrae, 2009). These IgG antibodies can bind to 
the fetal platelet antigens and cause thrombocytopenia in the fetus (Hindley 2016; Stavroe & 
McCrae, 2009). The major concern associated with fetal thrombocytopenia is intracranial 
hemorrhage, which can occur during delivery (Hindley 2016; Stavroe & McCrae, 2009). Clinical 
manifestations of intracranial hemorrhage may not appear until 2-5 days postpartum, which 
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necessitates frequent neurological monitoring with platelet counts less than 50,000 per mcL 
(Berkley & Kilpatrick, 2009; Hindley 2016; Stavroe & McCrae, 2009). However, retrospective 
studies have shown that although 15% of neonates born to mothers with ITP will present with a 
platelet count less than 50,000 per mcL, the rate of intracranial hemorrhage is less than 1% 
(Berkley & Kilpatrick, 2009).  
Prenatal Medical Management of ITP 
Although anesthesia providers are not directly involved in the medical management of 
ITP, a general understanding is required to safely deliver care during the intrapartum period. 
Management of ITP during the prenatal period depends on the patient’s clinical manifestations 
and platelet counts (Myers, 2012). A complete blood count (CBC) is typically drawn monthly in 
the first and second trimester, bimonthly in the third trimester, and weekly as the anticipated 
delivery date approaches (Myers, 2012; Provan et al., 2010). If severe thrombocytopenia or a 
rapid rate of platelet decline is noted, then more frequent CBC testing is required to assist in 
making decisions regarding the mode of delivery (Myers, 2012; Provan et al., 2010).  
If there is no evidence of excessive or spontaneous bleeding and platelet counts remain 
above 30,000 per mcL, treatment is not required until 36-weeks gestation or 10 days prior to the 
anticipated delivery date (Rajasekhar, Gernsheimer, Stasi, & James, 2013). However, oral 
corticosteroid therapy is recommended if delivery is imminent, platelet counts are below 30,000 
per mcL, or manifestations of bleeding are present (Rajasekhar et al., 2013). Oral corticosteroids 
are considered a first-line treatment and help to increase platelet counts by suppressing the 
immune response (Hindley, 2016; Rajasekhar et al., 2013). The corticosteroids of choice are 
prednisone or prednisolone (10-20 mg/day) because they do not readily cross the placenta 
(Rajasekhar et al., 2013). Unfortunately, there are risks associated with the use of corticosteroids 
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during pregnancy including weight gain, gestational diabetes, and maternal hypertension 
(Gernsheimer & McCrae, 2007; Hindley, 2016).  Therefore, corticosteroids should be avoided in 
women who have hypertensive or diabetic conditions (Gernsheimer & McCrae, 2007; Hindley, 
2016). An appropriate alternative therapy is intravenous immunoglobulin (IVIg) (1g/kg), which 
may be administered if significant side effects occur, corticosteroid therapy is ineffective, or a 
more rapid increase in platelets is required (Hindley, 2016; Provan et al., 2010; Rajasekhar et al., 
2013). Side effects associated with IVIg include vomiting, headache, and hypotension, which can 
be attenuated by decreasing the rate of infusion (Hindley, 2016).  
Generally speaking, platelet transfusion alone is not an effective treatment for ITP due to 
the rapid destruction of platelets associated with this syndrome (Provan et al., 2010). However, if 
a rapid increase in platelets is required for life-threatening bleeding or emergent delivery, platelet 
transfusion in conjunction with IVIg infusion is recommended (Provan et al., 2010; Rajasekhar 
et al., 2013; Stavroe & McCrae, 2009). A retrospective review of 40 patients with ITP who 
received concurrent platelet transfusion and IVIg for severe thrombocytopenia, active bleeding, 
and/or impending surgery concluded that the treatment was associated with minimal side effects, 
resolution of bleeding, and rapid restoration of platelet counts (Spahr & Rodgers, 2008). In fact, 
platelet transfusion not only reduces bleeding but will increase the post-transfusion platelet count 
by more than 20,000 per mcL in bleeding ITP patients (Provan et al., 2010). Unfortunately, there 
is limited evidence available regarding the optimal dose and timing for administration of IVIg 
and platelet therapy.  
Mode of Delivery 
 American Society of Hematology (ASH) guidelines on the intrapartum management of 
ITP recommend that maternal condition and obstetrical indicators dictate the mode of delivery 
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(Rajasekhar et al., 2013). Previous evidence indicated that elective cesarean section reduced the 
risk of fetal intracranial hemorrhage. However, this evidence has been dispelled by numerous 
studies over the last two decades (Stavroe & McCrae, 2009). Gasim (2011) conducted a 
retrospective study of 38 pregnancies with known ITP in which 14 parturients delivered by 
cesarean section and 24 underwent vaginal delivery. The study reported a low incidence of poor 
neonatal outcomes that were unrelated to the mode of delivery and concluded that routine use of 
cesarean section should be avoided (Gasim, 2011). Similarly, a retrospective study spanning 
from 1988 to 2007 reviewed 104 pregnancies complicated by ITP and noted no association 
between intracranial hemorrhage and mode of delivery (Belkin, Levy, & Sheiner 2009).  
Even if a trial of labor is deemed appropriate, the risk of cesarean section is present with 
every labor (Stavroe & McCrae, 2009). Therefore, the primary concern during parturition is 
maintaining a platelet count that will minimize the risk of maternal hemorrhage during both 
vaginal and cesarean delivery (Stavroe & McCrae, 2009). The ASH guidelines recommend a 
platelet count of 50,000 per mcL to minimize the risk of maternal hemorrhage during both 
vaginal and cesarean delivery because the incidence of hemorrhage is rare with platelet counts 
above this value (Myers, 2012; Stavroe & McCrae, 2009; Rajasekhar et al., 2013). If emergency 
delivery is required with a platelet count under 50,000 per mcL, platelet transfusion in 
conjunction with IVIg is recommended (Provan et al., 2010; Rajasekhar et al., 2013; Stavroe & 
McCrae, 2009).   
Neuraxial Anesthesia in the parturient with ITP 
 Management of ITP in pregnancy requires collaboration among the obstetrician, 
hematologist, anesthetist, and neonatologist (Hindley, 2016; Myers, 2012; Provan et al., 2010). 
Anesthesia should be consulted early in the pregnancy to make decisions regarding the analgesic 
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and anesthetic plan for delivery (Myers, 2012). Early pregnancy anesthetic counseling for 
women with ITP should include an explanation that neuraxial anesthesia may not be possible due 
to the platelet count at the time of delivery (Myers, 2012). In addition, education should be 
provided regarding the benefits, risks, and alternatives to neuraxial anesthesia (Myers, 2012). 
When a parturient with ITP is admitted, anesthesia should be notified, and the most recent 
platelet count should be made available (Hindley, 2016).  
Currently, neuraxial anesthesia is considered the favorable method of obstetric analgesia 
and anesthesia (Nagelhout & Plaus, 2014). It has significant advantages over general anesthesia 
as a primary anesthetic for cesarean section including decreased risk of maternal mortality, pain 
relief, blood pressure stability, and more favorable neonatal outcomes (Provan et al., 2010; 
Nagelhout & Plaus, 2014). Unfortunately, coagulopathy is considered a contraindication to 
neuraxial anesthesia administration because it places the parturient at increased risk of spinal- 
epidural hematoma (Bernstein et al., 2016; Nagelhout & Plaus, 2014). Controversy exists 
regarding the lowest safe platelet count required for administration of neuraxial anesthesia in the 
parturient with thrombocytopenia. The ASH Clinical Practice Guide on Thrombocytopenia in 
Pregnancy does not recommend a definitive minimum platelet count for placement of neuraxial 
anesthesia in parturients with ITP (Rajasekhar et al., 2013). Instead, the guide suggests that a 
minimum platelet count of 80,000 per mcL may be appropriate but ultimately recommends that 
local practices and clinician discretion should guide administration of neuraxial anesthesia 
(Rajasekhar et al., 2013). Similarly, the International Consensus Report on the Investigation and 
Management of ITP also does not recommend a minimum platelet count for neuraxial anesthesia 
(Provan et al., 2010). However, studies included within the report indicate that a lower threshold 
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of 75,000 per mcL may be appropriate (Provan et al., 2010). Additionally, Huang, McKenna, and 
Babins (2014) report that: 
No recommendations exist from the American Society of Regional Anesthesia and Pain 
Medicine, the European Society of Regional Anesthesia, The American Society of 
Anesthesiologists, or the American College of Obstetrics and Gynecology addressing when 
it is safe to administer neuraxial techniques in the parturient with ITP or other 
coagulopathies (p. 128).  
Due to inadequate evidence and conflicting reports, a minimum required platelet count cannot be 
supported. Until a consensus can be reached, it is suggested that the provision of neuraxial 
anesthesia be considered on an individual basis with the risks of the procedure carefully balanced 
against the benefits (Myers, 2012; Provan et al., 2010).  
 Several studies have proposed utilizing thromboelastography (TEG) and rotational 
thromboelastometry (ROTEM) to help guide safe anesthetic practices in the parturient with 
thrombocytopenia (Huang et al., 2014; Mauritz, Strouch, & Olufolabi, 2016; Provan et al., 
2010). ROTEM and TEG are point-of-care tests that are used to assess coagulation and provide 
information regarding clot formation, stabilization, and dissolution (Mauritz et al., 2016). 
According to Provan et al. (2010), “using this technique, thrombocytopenia can be evaluated 
against the prothrombotic state of pregnancy, rather than monitoring platelet function alone” (p. 
178). A prospective cohort study performed by Huang et al. (2014), utilized TEG in conjunction 
with platelet counts to assess the incidence of neurologic complications related to regional 
anesthesia in parturients with thrombocytopenia. The results from the three-year study suggest 
that neuraxial anesthesia can be safely performed in parturients with platelet counts greater than 
56,000 per mcL and a normal TEG result (Huang et al., 2014). Similarly, a case study performed 
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by Mauritz et al. (2016) reported utilizing ROTEM to evaluate platelet function and guide the 
anesthetic management of a high-risk parturient with thrombocytopenia. With the use of 
ROTEM, a cesarean section was performed under spinal anesthesia without complication 
(Mauritz et al., 2016). There is potential in utilizing TEG and ROTEM to assess the risk of 
administering neuraxial anesthesia in the parturient with ITP. However, a recommendation for its 
use cannot be made at this time.  
  As discussed earlier, the major risk associated with administering neuraxial anesthesia to 
thrombocytopenic patients is the development of a spinal-epidural hematoma (Bernstein et al., 
2016). A spinal-epidural hematoma is a collection of blood within the spinal neuraxis that can 
compress the spinal cord and nerve roots leading to irreversible neurologic dysfunction 
(Horlocker et al., 2010; Nagelhout & Plaus, 2014). The actual risk of developing neurological 
dysfunction following administration of neuraxial anesthesia is unknown (Horlocker et al., 
2010). The estimated incidence in the obstetric population is 1 in 168,000 after epidural 
administration and unknown after spinal administration (Bernstein et al., 2016). Lee et al. (2017) 
conducted a retrospective cohort study and systematic review that included a total of 1,524 
thrombocytopenic parturients. The study found that the risk of epidural hematoma was 11% for a 
platelet count less than 50,000 per mcL, 3% for 50,000 to 69,000 per mcL, and 0.2% for 70,000 
to 100,000 per mcL (Lee et al., 2017). Similarly, a study containing 499 parturients with platelet 
counts less than 100,000 per mcL reported the risk of spinal-epidural hematoma to be 0 to 0.6% 
(Goodier, Lu, Hebbar, Segal, & Goetzl, 2015). Factors associated with the development of a 
symptomatic hematoma include spinal cord abnormalities, difficult needle placement, 
coagulopathy, increased needle size, and catheter placement (Horlocker et al., 2010; Provan et 
al., 2010). Due to these risk factors, Provan et al. (2010) suggest that spinal anesthesia delivered 
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by an experienced clinician may be a safer neuraxial anesthetic option for thrombocytopenic 
patients. However, there is limited evidence regarding appropriate anesthetic techniques that 
minimize the risk of hematoma formation. Again, a thorough risk-benefit analysis should be 
performed prior to administering neuraxial anesthesia to a parturient with ITP (Myers, 2012; 
Provan et al., 2010).    
Anticipation and Management of Maternal Hemorrhage  
The major complication associated with ITP in the parturient, although low, is excessive 
or spontaneous hemorrhage during the intrapartum and postpartum periods (Berkley & 
Kilpatrick, 2009; Hindley, 2016). An integral component of obstetric anesthesia is developing a 
plan for the management of maternal hemorrhage (Nagelhout & Plaus, 2014). Due to the 
potential for maternal hemorrhage, a CBC should be drawn, and a large bore IV cannula should 
be inserted as a precautionary measure (Hindley, 2016). Typically, it is not routine to order a 
blood type and screen for healthy low-risk parturients (Apfelbaum et al., 2016). The decision to 
order a blood type and screen are based on the history, anticipated hemorrhagic complications, 
institutional policy, and provider assessment (Apfelbaum et al., 2016). If type specific blood is 
not available in the event of an emergency, type O-negative blood is an acceptable alternative 
(Apfelbaum et al., 2016). Additionally, resources for hemorrhagic emergencies should be readily 
available as they are associated with reduced maternal complications (Apfelbaum et al., 2016). 
The ASA Practice Guidelines for Obstetric Anesthesia recommend the following resources for 
obstetric hemorrhagic emergencies: large bore IV catheters, fluid warmers, blood bank resources, 
massive transfusion protocol, rapid transfusion devices, and cell salvage equipment (Apfelbaum 
et al., 2016).  
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Maternal hemorrhage should be considered when blood loss is greater than or equal to 
one liter or clinical manifestations of hypovolemia develop within 24 hours of parturition 
(Shields, Goffman, & Caughey, 2017). When maternal hemorrhage develops, anesthetic focus 
shifts from the delivery of analgesia and anesthesia to the maintenance of vital organ perfusion 
and oxygenation (Nagelhout & Plaus, 2014). If severe hemorrhage develops with regional 
anesthesia in place, it is recommended to consider rapid sequence induction of general anesthesia 
(Nagelhout & Plaus, 2014). General anesthesia utilizing anesthetic agents that result in minimal 
hemodynamic depression may be the most appropriate anesthetic technique in the event of 
severe hemorrhage (Apfelbaum et al., 2016). Furthermore, it allows the clinician to manage 
volume resuscitation, focus on hemodynamic support, and ensure patient comfort (Nagelhout & 
Plaus, 2014).  
Maternal hemorrhage requiring blood transfusion is the leading cause of maternal 
morbidity in the United States (Shields et al., 2017). Unfortunately, replacing intravascular 
volume at the rate it is being lost in severe hemorrhage may require the use of blood bank 
resources and massive transfusion protocols (Apfelbaum et al., 2016; Nagelhout & Plaus, 2014). 
Intraoperative cell salvage should be considered, especially in situations involving limited 
banked blood availability or patient refusal of banked blood administration (Apfelbaum et al., 
2016). Furthermore, a rapid increase in platelets may be required for thrombocytopenic 
parturients with life-threatening bleeding (Provan et al., 2010). As discussed earlier, platelet 
transfusion in conjunction with IVIg infusion may reduce bleeding by rapidly restoring platelet 
counts (Provan et al., 2010; Rajasekhar et al., 2013; Stavroe & McCrae, 2009). Ultimately, the 
utilization of a massive transfusion protocol and clear communication amongst the 
multidisciplinary care team will promote improved patient outcomes by initiating laboratory 
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studies, restoring fluid volume, correcting coagulopathies, and rectifying the primary cause of 
bleeding (Apfelbaum, 2016; Nagelhout & Plaus, 2014; Shields et al., 2017).  
Discussion 
The patient in this case review was undergoing elective, repeat cesarean section at 36-
weeks gestation with a history of chronic ITP. Antepartum management of the patient’s ITP was 
limited due to the fact that she did not present for prenatal care until late in the third trimester. 
Therefore, serial platelet counts were not drawn throughout the pregnancy, and the ITP was not 
medically managed with oral corticosteroids or IVIg therapy.  
Elective cesarean section was the patient’s only option for delivery due to her history of 
three previous cesarean sections and incomplete uterine rupture. This coincides with the 
evidence, which recommends that the maternal condition and obstetrical indicators should guide 
the mode of delivery. As previously discussed, a platelet count of 50,000 per mcL is 
recommended to minimize the risk of maternal hemorrhage during both vaginal and cesarean 
delivery. Although the platelet count was considered stable at 87,000 per mcL and no bleeding 
manifestations were noted, the major maternal complications associated with ITP in the 
parturient is hemorrhage. Therefore, precautionary measures were taken prior to the start of the 
case, which included maintaining communication with blood bank, having two units of typed 
and screened blood available in the operating room, obtaining two large bore IV catheters with 
blood tubing attached, and confirming that rapid transfusion devices were readily available. 
Likewise, this corresponds with the evidence presented within the review.  
The decision to perform spinal anesthesia as the primary anesthetic was based on the 
patient’s stable platelet count and absence of bleeding manifestations. This intervention may be 
considered controversial. Until a consensus is reached, the evidence suggests that a thorough 
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risk-benefit analysis is appropriate. Additionally, TEG and/or ROTEM were not utilized to 
further assess coagulation, though, there is limited evidence to support this intervention. The 
spinal anesthetic was placed in one attempt by an experienced anesthetist utilizing a 25-gauge 
pencil point spinal needle. It is feasible that these interventions may have minimized the patient’s 
risk of hematoma formation, however, the evidence is inconclusive.  
Conclusion 
ITP is an autoimmune disorder that accelerates the rate of platelet destruction and leads to 
persistent thrombocytopenia. Most pregnancies complicated by ITP are uneventful and result in 
good outcomes. However, frequent monitoring of maternal and fetal wellbeing as well as 
collaboration among the multidisciplinary care team members is required to mitigate 
complications.	Management of ITP ultimately depends on the patient’s clinical manifestations 
and platelet counts. These factors not only dictate prenatal medical management and mode of 
delivery, but also the anesthetic plan throughout parturition. 
Although it is well documented that the risk of spinal-epidural hematoma increases as the 
platelet count decreases, a decisively safe platelet count for the administration of neuraxial 
anesthesia in thrombocytopenic patients has yet to be identified. A consensus among national 
medical specialty societies needs to be achieved regarding this value. Additionally, emerging 
research on the utilization of TEG and ROTEM to help guide safe anesthetic practices in the 
parturient with thrombocytopenia is promising. However, further research is needed before 
definitive recommendations can be made.  
Undoubtedly, a parturient with ITP presents a unique challenge to the anesthesia care 
team that requires thorough anesthetic planning and vigilant monitoring. With the development 
of consistent guidelines among national medical specialty societies and further research 
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regarding the management of the condition, anesthetic management of this population can be 
improved.  
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Anesthetic	Considerations	for	the	
Parturient	with	Immune	
Thrombocytopenic	Purpura	
Leah	A.	Davis,	SRNA
Introduction
• Immune	thrombocytopenic	purpura	(ITP)	is	an	
autoimmune	disorder	that	accelerates	the	rate	of	
platelet	destruction	and	leads	to	persistent	
thrombocytopenia.	
• ITP	accounts	for	5%	of	pregnancy-associated	
thrombocytopenia.	
• The	condition	in	the	parturient	is	associated	with	
complications	that	include:
oMaternal	hemorrhage
o Fetal	intracranial	hemorrhage		
o Spinal-epidural	hematoma	with	neuraxial	anesthesia
Case	Information
• Planned	repeat	cesarean	section	for	
pregnancy	at	36-weeks	gestation	
• 23-year	old	female	
• 155	cm
• 90	kg
• No	known	drug	allergies
• ASA	physical	status	level	2
Pre-operative	Evaluation
• Past	Medical	History:
o Chronic	ITP
o Iron	deficiency	anemia	
• Surgical	History:
o 3	previous	cesarean	sections
o Laparoscopic	cholecystectomy	
• Obstetric	History:
o G4P3
o Late	prenatal	care	in	3rd trimester	
o No	medical	management	of	ITP	during	pregnancy
• Anesthetic	History:
o Uncomplicated	
Pre-operative	Evaluation	Continued
• Pre-operative	vital	signs:
o Heart	rate:	72/min
o Blood	pressure:	122/70	mmHg
o Respirations:	12/min
o Room	air	oxygen	saturations	(SpO2):	99%
o Temperature:	36.1° Celsius	
• Mallampati score:	2
• Pertinent	labs:
o HGB:	12.4	g/dL
o HCT:	37.2%
o PLT:	87,000/mcL (stable)
o Type	and	screened	for	2	units	PRBCs	(available	in	OR)
Anesthetic	Course
• Pre-op:
o 1L	bolus	LR	via	20-gauge	IV	catheter	
• Intrathecal	administration:
o Sitting	position,	one	attempt	at	L3-4	space
o 20-gauge	introducer	needle	and	25-gauge,	3.5	inch	pencil	point	spinal	needle	
o Injection	of	1.6	mL	0.75%	bupivacaine,	20	mcg	fentanyl,	and	0.2	mg	morphine	
o Level	of	blockade:	T6	distribution
• Spontaneously	breathing	with	nasal	cannula	at	3	L/min	
• Additional	18-gauge	IV	catheter	placed	with	NS	and	blood	tubing	attached
• Other	medications	administered:
o 100	mcg	phenylephrine	IV,	2	g	cefazolin	IV,	4	mg	ondansetron	IV,	1L	bag	LR	
with	20	units	oxytocin.	
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Intraoperative	Issues
• Hypotension:
o Treated	with	100	mcg	phenylephrine	IV	
• Nausea:
o Treated	with	4	mg	ondansetron	IV	
Post-operative	Course
• Total	procedure	time:	1	hour	and	25	minutes
• Neonate	transferred	to	NICU	and	parturient	transferred	to	PACU
• Complaint	of	itching	in	PACU
o Treated	with	25	mg	diphenhydramine	IV
• Intake/Output:
o Volume	replacement:
§ Normal	saline:	1000	mL
§ Lactated	ringers:	1400	mL
§ Lactate	ringers	with	20	units	oxytocin:	500	mL
o Estimated	blood	loss:	500	mL
o Urine	Output:	400	mL
• Patient	and	neonate	discharged	home	on	post-operative	day	4	
Pathophysiology
• ITP	is	an	autoimmune	disorder	that	involves	the	
formation	of	IgG	antiplatelet	antibodies	that	recognize	
specific	antigens	on	platelet	membranes.	
• The	binding	of	the	IgG	antibodies	to	the	platelet	
membrane	marks	the	platelet	for	destruction	by	the	
reticuloendothelial	system	in	the	spleen.	
• This	accelerates	the	rate	of	platelet	destruction	and	
leads	to	persistent	thrombocytopenia.	
• Most	commonly	presents	as	an	asymptomatic	disorder	
that	is	detected	with	routine	lab	testing.	
• Some	may	present	with	a	history	of	gingival	bleeding,	
epistaxis,	easy	bruising,	and/or	petechiae.	
(Berkley	&	Kilpatrick,	2009;	Stavroe &	McCrae,	2009;	Wysznyski et	al.,	2016)
Complications
• Current	literature	indicates	that	women	with	ITP	have	a	low	
risk	of	complications	and	can	safely	tolerate	pregnancy.	
• Major	complication	for	the	parturient	is	hemorrhage.
• Major	complication	in	the	fetus	is	the	development	of	fetal	
thrombocytopenia	and	subsequent	fetal	intracranial	
hemorrhage.	
o Maternal	IgG	antibodies	are	actively	transported	into	fetal	
circulation	thru	the	placenta.
o Highest	risk	of	hemorrhage	occurs	in	neonates	with	platelet	
counts	less	than	50,000/mcL.
o Intracranial	hemorrhage	can	occur	during	delivery,	but	may	not	
appear	until	2-5	days	postpartum.
(Berkley	&	Kilpatrick,	2009;	Hindley,	2016;	Provan et	al.,	2010; Stavroe &	McCrae,	2009)
Prenatal	Medical	Management
• CBC	should	be	drawn:
o Monthly	in	the	1st	and	2nd	trimester,	bimonthly	in	the	3rd	trimester,	
and	weekly	as	the	anticipated	delivery	date	approaches.
o More	frequent	monitoring	may	be	required	depending	on	the	severity	
of	the	thrombocytopenia.	
• Treatment	is	not	required	until	36-weeks	gestation	or	10	days	
prior	to	the	anticipated	delivery	date	if	there	is	no	evidence	of	
bleeding	and	platelet	counts	remain	above	30,000/mcL.
• Treatment	is	recommended	if	delivery	is	imminent,	platelet	
counts	are	below	30,000/mcL,	or	bleeding	is	present.	
o First	line	therapy	=	oral	corticosteroids	(prednisone	or	prednisolone)	
o Alternative	therapy	=	intravenous	immunoglobulin	(IVIg)
(Hindley,	2016;	Gernsheimer &	McCrae,	2007;	Provan et	al.,	2010;	Rajasekhar,	Gernsheimer,	Stasi,	&	James	,	2013)
Prenatal	Medical	Management	Continued
• Platelet	transfusion	in	conjunction	with	IVIg	infusion	is	
recommended	if	a	rapid	increase	in	platelets	is	required	for	
life-threatening	bleeding	or	emergent	delivery.		
o Platelet	transfusion	alone	is	not	an	effective	treatment	for	ITP	
due	to	the	syndrome’s	rapid	destruction	of	platelets.
o A	retrospective	review	by	Spahr &	Rodgers	(2008)	concluded	
that	concurrent	platelet	transfusion	and	IVIg	treatment	was	
associated	with	minimal	side	effects,	resolution	of	bleeding,	and	
rapid	increase	in	platelet	counts.	
o Provan et	al.	(2010)	found	that	platelet	transfusion	in	
conjunction	with	IVIg will	increase	the	post-transfusion	platelet	
count	by	more	than	20,000/mcL in	bleeding	ITP	patients.	
(Provan et	al.,	2010;	Rajasekhar et	al.,	2013;	Spahr &	Rodgers,	2008;	Stavroe &	McCrae,	2009)
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Mode	of	Delivery
• Maternal	condition	and	obstetrical	indicators	dictate	the	mode	of	
delivery.	
• Previous	evidence	indicated	that	elective	cesarean	section	reduced	
the	risk	of	fetal	intracranial	hemorrhage.	However:
o Belkin,	Levy,	&	Sheiner (2009)	conducted	a	retrospective	study	that	found	
no	association	between	intracranial	hemorrhage	and	mode	of	delivery
and	concluded	that	routine	use	of	cesarean	section	should	be	avoided.
o Similarly,	a	retrospective	study	by	Gasim (2011)	reported	a	low	incidence	
of	poor	neonatal	outcomes	that	were	unrelated	to	the	mode	of	delivery.	
• The	primary	concern	during	parturition	is	maintaining	a	platelet	
count	greater	than	50,000/mcL to	minimize	the	risk	of	hemorrhage	
during	both	vaginal	and	cesarean	delivery.	
(Belkin	et	al.,	2009;	Gasim,	2011;	Provan et	al.,	2010;	Rajasekhar et	al.,	2013;	Stavroe &	McCrae,	2009).	
Neuraxial	Anesthesia	
• ITP	increases	the	risk	of	spinal-epidural	hematoma	formation.	
• No	definitive	recommendation	exists	regarding	the	minimally	
safe	platelet	count	required	for	administration	of	neuraxial	
anesthesia	in	the	parturient	with	thrombocytopenia.	
o The	ASH	Clinical	Practice	Guide	on	Thrombocytopenia	in	Pregnancy	
suggests	that	a	minimum	platelet	count	of	80,000/mcL may	be	
appropriate.
o Studies	included	within	the	International	Consensus	Report	on	the	
Investigation	and	Management	of	ITP	indicate	that	a	lower	threshold	
of	75,000/mcL may	be	appropriate.
o No	recommendations	exist	from	the	American	Society	of	Regional	
Anesthesia	and	Pain	Medicine,	the	European	Society	of	Regional	
Anesthesia,	The	American	Society	of	Anesthesiologists,	or	the	
American	College	of	Obstetrics	and	Gynecology.			
(Bernstein	et	al.,	2016;	Huang,	McKenna,	&	Babins,	2014;	Myers,	2012;	Nagelhout &	Plaus,	2014;	Provan et	
al.,	2010;	Rajasekhar et	al.,	2013)
Neuraxial	Anesthesia	Continued	
• Several	studies	have	proposed	utilizing	
thromboelastography (TEG)	and	rotational	
thromboelastometry (ROTEM)	to	guide	safe	anesthetic	
practices	in	the	parturient	with	thrombocytopenia.	
o The	use	of	TEG	and	ROTEM	allows	thrombocytopenia	to	be	
evaluated	against	the	prothrombotic	state	of	pregnancy,	rather	
than	monitoring	platelet	function	alone.	
o The	results	from	a	prospective	cohort	study	by	Huang	et	al.	
(2014)	suggest	that	neuraxial	anesthesia	can	be	safely	
performed	in	parturients	with	platelet	counts	greater	than	
56,000/mcL and	a	normal	TEG	result.
o Similarly,	a	case	study	performed	by	Mauritz,	Strouch,	and	
Olufolabi (2016) reported	utilizing	ROTEM	to	safely	perform	a	
cesarean	section	under	spinal	anesthesia	in	a	high-risk	
parturient	with	thrombocytopenia.	
(Huang	et	al.,	2014;	Mauritz et	al.,	2016;	Provan et	al.,	2010	)
Spinal-Epidural	Hematoma	
• A	spinal-epidural	hematoma	is	a	collection	of	blood	that	can	
compress	the	spinal	cord/nerve	roots	leading	to	irreversible	
neurologic	dysfunction.
o A	retrospective	cohort	study	by	Lee	et	al.	(2017)	found	that	the	risk	of	
epidural	hematoma	was	11%	for	a	platelet	count	less	than	
50,000/mcL,	3%	for	50,000	to	69,000/mcL,	and	0.2%	for	70,000	to	
100,000/mcL.
o Similarly,	a	study	by	Goodier,	Lu,	Hebbar,	Segal,	&	Goetzl (2015)	
containing	parturients	with	platelet	counts	less	than	100,000/mcL
reported	the	risk	of	spinal-epidural	hematoma	to	be	0	to	0.6%.
• Risk	factors	for	the	development	of	a	symptomatic	hematoma	
include	spinal	cord	abnormalities,	difficult	needle	placement,	
coagulopathy,	increased	needle	size,	and	catheter	placement.
o Provan et	al.	(2010)	suggests	that	spinal	anesthesia	delivered	by	an	
experienced	clinician	may	be	a	safer	neuraxial	anesthetic	option	for	
thrombocytopenic	patients.	
(Bernstein	et	al.,	2016;	Goodier et	al.,	2015;	Horlocker et	al.,	2010;	Lee	et	al.,	2017;	Nagelhout &	
Plaus,	2014;	Provan et	al.,	2010)
Management	of	Maternal	Hemorrhage
• Maternal	hemorrhage	requiring	blood	transfusion	is	the	leading	
cause	of	maternal	morbidity	in	the	United	States.	
• If	severe	hemorrhage	develops	with	regional	anesthesia	in	place,	it	
is	recommended	to	consider	rapid	sequence	induction	of	general	
anesthesia.
o This	allows	the	clinician	to	manage	volume	resuscitation,	focus	on	
hemodynamic	support,	and	ensure	patient	comfort.
• Intraoperative	cell	salvage	should	be	considered.	
o Especially	important	in	situations	involving	limited	banked	blood	
availability	or	patient	refusal	of	banked	blood	administration.
• A rapid	increase	in	platelets	may	be	required	for	thrombocytopenic	
parturients	with	life-threatening	bleeding.
o Platelet	transfusion	in	conjunction	with	IVIg	infusion	may	reduce	
bleeding	by	rapidly	restoring	platelet	counts.
(Apfelbaum et	al.,	2016;	Nagelhout &	Plaus,	2014;	Provan et	al.,	2010;	Shields,	Goffman,	&	Caughey,	2017)	
Recommendations
• Frequent	monitoring	of	maternal	and	fetal	wellbeing	as	
well	as	collaboration	among	the	multidisciplinary	care	team	
is	required	to	mitigate	complications.	
• Prenatal	management	should	include	serial	CBC	monitoring	
and	administration	of	oral	corticosteroids	or	IVIg	depending	
on	clinical	manifestations	and	maternal	platelet	counts.
• The	routine	use	of	cesarean	section	should	be	avoided.	The	
mode	of	delivery	is	dependent	on	maternal	condition	and	
obstetrical	indicators.	
• The	primary	goal	during	delivery	is	to	minimize	the	risk	of	
maternal	hemorrhage	by	maintaining	a	platelet	count	
greater	than	50,000/mcL during	both	vaginal	and	cesarean	
delivery.
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Recommendations	Continued	
• life-threatening	bleeding	or	emergent	delivery	may	
necessitate	platelet	transfusion	in	conjunction	with	IVIg	
infusion.		
o Further	research	is	needed	regarding	the	optimal	dose	and	
timing	for	administration	of	IVIg	and	platelet	therapy.	
• Further	research	is	needed	regarding	the	minimally	
safe	platelet	count	required	for	administration	of	
neuraxial	anesthesia.
• Further	research	is	needed	regarding	the	use	of	
TEG/ROTEM	to	help	guide	safe	neuraxial	anesthetic	
practices.	
Conclusion
• The	patient	underwent	repeat	cesarean	section	at	36-
weeks	gestation	with	a	history	of	chronic	ITP.	
o Serial	platelet	counts	were	not	drawn	and	the	ITP	was	not	
medically	managed.	
• Cesarean	section	was	the	patient’s	only	option	for	delivery	
due	to	her	history	of	3 previous	cesarean	sections	and	
incomplete	uterine	rupture.	
• The	platelet	count	was	stable	at	87,000/mcL and	no	
bleeding	manifestations	were	noted.
o Precautionary	measures	for	hemorrhage	were	taken	prior	to	
the	start	of	the	case.	
o TEG	and/or	ROTEM	were	not	utilized	to	further	assess	
coagulation.	
o The	spinal	was	placed	in	one	attempt	by	an	experienced	
anesthetist	utilizing	a	25-gauge	pencil	point	spinal	needle	
Conclusion	Continued	
• A	parturient	with	ITP	presents	a	challenge	to	
the	anesthesia	care	team	that	requires	
thorough	anesthetic	planning	and	vigilant	
monitoring.	
• With	the	development	of	consistent	
guidelines	and	further	research,	anesthetic	
management	of	this	population	can	be	
improved.	
References
Apfelbaum,	J.	L.,	Hawkins,	J.	L.,	Bucklin,	B.	A.,	Connis,	R.	T.,	Gambling,	D.	R.,	Mhyre,	J.,	Nickinovich,	D.	G.,	Sherman,	H.,	Tsen,	L.	C.,	&	Yaghmour,	E.	
A.	(2016).	Practice	guidelines	for	obstetric	anesthesia.	Anesthesiology,	124(2),	270-300.	doi:	10.1097/ALN.0000000000000935.
Belkin,	A.,	Levy,	A.,	&	Sheiner,	E.	(2009).	Outcomes	and	complications	of	pregnancy	in	women	immune	thrombocytopenic	purpura.	Journal	of	
Maternal	Fetal	 Neonatal	Medicine,	22(11),	1081-1085.	doi:	10.3109/14767050903029592.	
Berkley,	M.	F.	&	Kilpatrick,	S.	J.	(2009).	Thrombocytopenia	in	pregnancy:	Making	the	differential	diagnosis.	Contemporary	OB/GYN,	54(1),	36-43.	
Retrieved	from	https://ezproxylr.med.und.edu:2420/ehost/pdfviewer/pdfviewer?vid=16&sid=d2470aab-477e-49ed-aa63	
074a0f77bff6%40sessionmgr120.	
Bernstein,	J.,	Hua,	B.,	Kahana,	M.,	Shaparin,	N.,	Yu,	S.,	&	Davila-Velazquez,	J.	(2016).	Neuraxial	anesthesia	in	parturients	with	low	platelet	counts.	
Anesthesia	and	Analgesia,	123(1),	165-167.	doi:	10.	1213/ANE.0000000000001312.	
Hindley,	C.	(2016).	Immune	thrombocytopaenia in	pregnancy:	Key	principles	for	the	midwife.	British	Journal	of	Midwifery,	24(11),	768-772.	
Retrieved	from	 https://ezproxylr.med.und.edu:2426/ehost/pdfviewer/pdfviewer?vid=10&sid=479c5374-
b931-4dc2-bfb0-121de71e0715%40sessionmgr4008.	
Gasim,	T.	(2011).	Immune	thrombocytopenic	purpura	in	pregnancy:	A	reappraisal	of	obstetric	management	and	outcome.	Journal	of
Reproductive	Medicine,	56(3-4),	163-168.	Retrieved	from	https://ezproxylr.med.und.edu:2243/pubmed/21542536.
Gernsheimer,	T.	&	McCrae,	K.	R.	(2007).	Immune	thrombocytopenic	purpura	in	pregnancy.	Current	Opinion	in	Hematology,	14(5),	574-580.	doi:	
10.1097/MOH.0b013e3282bf6dc2.
Goodier,	C.	G.,	Lu,	J.	T.,	Hebbar,	L.,	Segal,	B.	S.,	&	Goetzl,	L.	(2015).	Neuraxial	anesthesia	in	parturients	with	thrombocytopenia:	A
multisite	retrospective	cohort	study.	Anesthesia	&	Analgesia,	121(4),	988-991.	doi:	10.1213/ANE.0000000000000882.	
Horlocker,	T.	T.,	Wedel,	D.	J.,	Rowlingson,	J.	C.,	Enneking,	F.	K.,	Kopp,	S.	L.,	Benzon,	H.	T.,	Brown,	D.	L.,	Heit,	J.	A.,	Mulroy,	M.F.,	Rosenquist,	R.	W.,	
Tryba,	M.,	&	Yuan,	C.	S.	(2010).	Regional	anesthesia	in	the	patient	receiving	antithrombotic	or	thrombolytic	therapy.	Regional	
Anesthesia	and	Pain	Medicine,	35(1),	64-101.	doi:	10.1097/AAP.0b013e3181c15c70.
Huang,	J.,	Mckenna,	N.,	&	Babins,	N.	(2014).	Utility	of	thromboelastography during	neuraxial	blockade	in	the	parturient	with
thrombocytopenia.	AANA	Journal,	82(2),	127-130.	Retrieved	from	
https://ezproxylr.med.und.edu:2420/ehost/pdfviewer/pdfviewer?vid=	12&sid=aa8c7578-d139-4aef-b42a-
6b01332143d6%40sessionmgr120.
References	Continued	
Lee,	L.	O.,	Bateman,	B.	T.,	Kheterpal,	S.,	Klumpner,	T.	T.,	Housey,	M.,	Aziz,	M.	F.,	Hand,	K.	W.,	MacEachern,	M.,	Goodier,	C.	G.,	Bernstein,	J.,	&	
Bauer,	M.	E.	(2017).	Risk	of	epidural	hematoma	after	neuraxial	techniques	in	thrombocytopenic	parturients:	A	reportfrom the	
multicenter	perioperative	outcomes	group.	Anesthesiology,	126(6),	1053-1063.	doi:	10.	1097/ALN.0000000000001630.	
Mauritz,	A.	A.,	Strouch,	Z.	Y.,	&	Olufolabi,	A.	J.	(2016).	A	conundrum:	General	or	neuraxial	anesthesia	and	the	use	of	ROTEM.	Journal	of	Clinical	
Anesthesia,	32,	159-161.	doi:	http://dx.doi.org/10.	1016/j.jclinane.2016.03.002.	
Myers,	B.	(2012).	Diagnosis	and	management	of	maternal	thrombocytopenia	in	pregnancy.	British	Journal	of	Haematology,	158(1),	3-15.	doi:	
10.1111/j.1365-2141.2012.09135.x.
Nagelhout,	J.	J.	&	Plaus,	K.	A.	(2014).	Nurse	anesthesia.	St.	Louis,	MO:	Elsevier	Saunders.	
Provan,	D., Stasi,	R., Newland,	A., Blanchette,	V.S., Bolton-Maggs,	P., Bussel,	J.B., Chong,	B., Cines,	D., Gernsheimer,	T., Godeau,	B., Grainger,	
J., Greer,	I., Hunt,	B., Imbach,	P., Lyons,	G., McMillan,	R., Rodeghiero,	F., Sanz,	M., Tarantino,	M., Watson,	S., Young,	
J., & Kuter,	D. (2010). International	consensus	report	on	the	investigation	and	management	of	primary	immune	
thrombocytopenia. Blood, 115, 168–186.	doi:	https://doi.org/10.1182/blood-2009-06-225565.
Rajasekhar,	A.,	Gernsheimer,	T.,	Stasi,	R.,	&	James,	A.	H.	(2013).	2013	clinical	practice	guideline	on	thrombocytopenia	in	pregnancy.	American	
Society	of	Hematology.	Retrieved	from	http://www.hematology.org/Clinicians/Guidelines-Quality/Guidelines.aspx.	
Shields,	L.	E.,	Goffman,	D.,	&	Caughey,	A.	B.	(2017).	Practice	bulletin	No.	183:	Postpartum	hemorrhage.	Obstetrics	&	Gynecology,	130(4),	168-
186.	doi:	10.1097/AOG.0000000000002351.
Spahr,	J.	E.	& Rodgers, G.	M.	(2008).	Treatment	of	immune-mediated	thrombocytopenia	purpura	with	concurrent	intravenous	
immunoglobulin	and	platelet	transfusion:	A	retrospective	review	of	40	patients. American	Journal	of	Hematology,	83(2),	122-
125.	Retrieved	from	https://www.ncbi.nlm.nih.gov/pubmed/17874448?access_num=17874448&link_type=MED&sso-
checked=true&dopt=Abstract.
Stavroe,	E.	&	McCrae,	K.	R.	(2009).	Immune	thrombocytopenia	in	pregnancy.	Hematology/Oncology	Clinics	of	North	America,	23(6),	1299-
1316.	doi:	10.1016/j.hoc.2009.08.005.
Wysznyski,	D.	F.,	Carman,	W.	J.,	Cantor,	A.	B.,	Graham,	J.	M.,	Kunz,	L.	H.,	Slavotinek,	A.	M.,	Kirby,	R.	S.,	&	Seeger,	J.	(2016).	Pregnancy	and
birth	outcomes	among	women	with	idiopathic	thrombocytopenic	purpura.	Journal	of	Pregnancy. Retrieved	from
http://dx.doi.org/10.1155/2016/8297407.	
Thank	You
Are	There	Any	Questions?
Thank	You
Are	There	Any	Questions?
